Tower Research Capital (TRC)’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-12,675
| Closed | -$228K | – | 5347 |
|
|
2020
Q2 | $228K | Buy |
+12,675
| New | +$176K | 0.01% | 1685 |
|
|
2020
Q1 | – | Sell |
-801
| Closed | -$19K | – | 4386 |
|
|
2019
Q4 | $19K | Sell |
801
-770
| -49% | -$21.2K | ﹤0.01% | 1975 |
|
|
2019
Q3 | $42K | Buy |
+1,571
| New | +$44.1K | ﹤0.01% | 1931 |
|
|
2019
Q2 | – | Sell |
-449
| Closed | -$16K | – | 4644 |
|
|
2019
Q1 | $16K | Buy |
+449
| New | +$13K | ﹤0.01% | 2422 |
|
|
2018
Q4 | – | Sell |
-75
| Closed | -$2K | – | 4634 |
|
|
2018
Q3 | $2K | Buy |
+75
| New | +$2.45K | ﹤0.01% | 3522 |
|
|
2018
Q2 | – | Sell |
-145
| Closed | -$5K | – | 4303 |
|
|
2018
Q1 | $5K | Buy |
+145
| New | +$6.36K | ﹤0.01% | 2746 |
|
|
2017
Q4 | – | Sell |
-3,223
| Closed | -$174K | – | 4283 |
|
|
2017
Q3 | $174K | Buy |
3,223
+3,120
| +3,029% | +$183K | 0.01% | 874 |
|
|
2017
Q2 | $6K | Buy |
103
+3
| +3% | +$120 | ﹤0.01% | 1941 |
|
|
2017
Q1 | $4K | Sell |
100
-2,789
| -97% | -$88.8K | ﹤0.01% | 2392 |
|
|
2016
Q4 | $65K | Buy |
2,889
+1,021
| +55% | +$19.9K | 0.01% | 1247 |
|
|
2016
Q3 | $43K | Buy |
1,868
+1,468
| +367% | +$34.5K | ﹤0.01% | 1230 |
|
|
2016
Q2 | $9K | Buy |
+400
| New | +$9.9K | ﹤0.01% | 2964 |
|
|
2016
Q1 | – | Sell |
-256
| Closed | -$13K | – | 5291 |
|
|
2015
Q4 | $13K | Buy |
+256
| New | +$12.4K | ﹤0.01% | 1833 |
|
|
2015
Q3 | – | Sell |
-1,140
| Closed | -$52K | – | 5105 |
|
|
2015
Q2 | $52K | Sell |
1,140
-1,640
| -59% | -$66K | ﹤0.01% | 1337 |
|
|
2015
Q1 | $106K | Buy |
+2,780
| New | +$95.5K | 0.01% | 840 |
|
|
2014
Q3 | – | Sell |
-456
| Closed | -$13K | – | 5091 |
|
|
2014
Q2 | $13K | Sell |
456
-5
| -1% | -$121 | ﹤0.01% | 2172 |
|
|
2014
Q1 | $12K | Sell |
461
-3,067
| -87% | -$81.8K | ﹤0.01% | 2459 |
|
|
2013
Q4 | $91K | Buy |
3,528
+753
| +27% | +$18.3K | 0.02% | 920 |
|
|
2013
Q3 | $74K | Buy |
2,775
+418
| +18% | +$9.9K | 0.01% | 1571 |
|
|
2013
Q2 | $58K | Buy |
+2,357
| New | +$46.8K | ﹤0.01% | 822 |
|
Tower Research Capital (TRC)'s PTLA Position: Q3 2020 in Review
Tower Research Capital (TRC) sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 12,675 shares — an estimated $228K sold.
Tower Research Capital (TRC) first reported a position in PTLA in Q2 2013 and held it in 20 quarters. The position peaked at $228K in Q2 2020. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Tower Research Capital (TRC) reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Tower Research Capital (TRC) sold 12,675 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $228K.
- Tower Research Capital (TRC) first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 20 quarters.
- Tower Research Capital (TRC)'s Portola Pharmaceuticals, Inc. position peaked at $228K in Q2 2020.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2020, filed 16 Nov 2020.